BioMarin Pharmaceutical (BMRN) News Today

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has seen analyst optimism drive its stock higher, with several firms boosting ratings, price targets and earnings forecasts over the past 24 hours.

• Positive Sentiment: BMO Capital Markets initiated coverage on BMRN with a “buy” rating, citing strong potential in its late‐stage pipeline. BioMarin Pharmaceutical (BMRN) Gets a Buy from BMO Capital
• Positive Sentiment: Wedbush reiterated an “outperform” rating on BMRN, pointing to encouraging clinical data updates. BioMarin Pharmaceutical (NASDAQ:BMRN) Earns "Outperform" Rating from Wedbush
• Positive Sentiment: Cantor Fitzgerald raised its FY2025 EPS estimate for BMRN to $3.60 from $3.58, reflecting stronger-than-expected sales momentum. Cantor Fitzgerald Has Positive View of BMRN FY2025 Earnings
• Positive Sentiment: The same firm also lifted its FY2026 EPS forecast to $4.84 from $4.29, driven by anticipated international growth. Research Analysts Offer Predictions for BMRN FY2026 Earnings
• Positive Sentiment: Guggenheim upped its price target on BMRN to $106 from $101 and maintained a “buy” rating, citing attractive risk/reward. Guggenheim Forecasts Strong Price Appreciation for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock
• Neutral Sentiment: Yahoo Finance published updated BMRN stock forecasts, detailing a wide range of price targets but no new consensus rating. BioMarin Pharmaceutical Inc. (BMRN) Stock forecasts
• Neutral Sentiment: MSN included BMRN on its healthcare watchlist, signaling interest alongside broader sector caution. 1 Healthcare Stock on Our Watchlist and 2 We Find Risky